Scholarlink

Purpose <p>Evidence regarding the optimal dose of paroxetine for lifelong premature ejaculation (LPE) with minimal adverse effects remains limited. This study evaluated the efficacy and safety of different paroxetine doses in patients with LPE.</p> Methods <p>The study recruited 100 LPE patients. Group (A) included 50 randomized LPE patients who received 12.5&#xa0;mg paroxetine daily after breakfast for 3&#xa0;months. Group (B) included 50 randomized LPE patients who received 20&#xa0;mg paroxetine daily after breakfast for 3&#xa0;months. After a 2-week washout, a crossover was executed for 3&#xa0;months.</p> Results <p>Groups A and B demonstrated statistically significant increases in the scores of the Arabic index of premature ejaculation (AIPE) and the male sexual quality of life (QOL) throughout the follow-up period. Furthermore, upper and lower bounds of 95% confidence interval using estimates of fixed effects demonstrated significant changes in sequence in group A versus group B, treatment in group A versus group B and geometric mean intravaginal ejaculation latency time (IELT) in group A versus group B (− 4.13, − 0.26; − 4.16, − 0.27; − 8.02, − 4.15; <i>p</i> = 0.026 0.026, 0, respectively). Notably, upper and lower bounds of 95% confidence interval using estimates of fixed effects demonstrated significant changes in the occurrence of complications in group A versus group B (− 0.35, − 0.01, <i>p</i> = 0.041, respectively).</p> Conclusion <p>12.5&#xa0;mg paroxetine may be preferentially prescribed over 20&#xa0;mg as it shows a comparable efficacy with lower adverse events and subsequent better tolerability and male sexual QOL.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of the efficacy and safety of different doses of daily paroxetine in patients with lifelong premature ejaculation: a prospective randomized crossover study

  • 期刊论文

  • 发表日期：

    2025年12月4日

查看全文
  • Sameh Fayek GamalEl Din,
  • Ahmed Raef Sadek,
  • Mohamed Yousry Elamir,
  • Mohamed Ahmed Ateya,
  • Hesham Hanafy Saber,
  • Mahmoud Fawzy Ghaly

摘要

Purpose

Evidence regarding the optimal dose of paroxetine for lifelong premature ejaculation (LPE) with minimal adverse effects remains limited. This study evaluated the efficacy and safety of different paroxetine doses in patients with LPE.

Methods

The study recruited 100 LPE patients. Group (A) included 50 randomized LPE patients who received 12.5 mg paroxetine daily after breakfast for 3 months. Group (B) included 50 randomized LPE patients who received 20 mg paroxetine daily after breakfast for 3 months. After a 2-week washout, a crossover was executed for 3 months.

Results

Groups A and B demonstrated statistically significant increases in the scores of the Arabic index of premature ejaculation (AIPE) and the male sexual quality of life (QOL) throughout the follow-up period. Furthermore, upper and lower bounds of 95% confidence interval using estimates of fixed effects demonstrated significant changes in sequence in group A versus group B, treatment in group A versus group B and geometric mean intravaginal ejaculation latency time (IELT) in group A versus group B (− 4.13, − 0.26; − 4.16, − 0.27; − 8.02, − 4.15; p = 0.026 0.026, 0, respectively). Notably, upper and lower bounds of 95% confidence interval using estimates of fixed effects demonstrated significant changes in the occurrence of complications in group A versus group B (− 0.35, − 0.01, p = 0.041, respectively).

Conclusion

12.5 mg paroxetine may be preferentially prescribed over 20 mg as it shows a comparable efficacy with lower adverse events and subsequent better tolerability and male sexual QOL.